 This was a randomized, placebo-controlled, double-blind study of vismodegib GDC-0449 added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer CRC, with treatment until disease progression. Patients received either FOLFOX FOLleucovorin calcium folinic acid, Ffluorouracil, OXoxaliplatin or FOLFIRI FOLleucovorin calcium folinic acid Ffluorouracil, IRIirinotecan hydrochloride chemotherapy with bevacizumab. The decision of which regimen FOLFOX or FOLFIRI to use was made by the treating physician and patient. Patients were randomized to receive vismodegib or placebo and were stratified based on the chemotherapy regimen chosen and whether or not Response Evaluation Criteria in Solid Tumors RECIST measurable disease was present at baseline. 